Dashboard
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.40 times
- Poor long term growth as Net Sales has grown by an annual rate of 1.71% and Operating profit at 8.20% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.40 times
- The company has reported losses. Due to this company has reported negative ROE
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CAD 178 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.65
-21.11%
1.96
Total Returns (Price + Dividend) 
HLS Therapeutics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

HLS Therapeutics Hits Day Low of CAD 4.51 Amid Price Pressure
HLS Therapeutics, Inc. faced a notable stock decline today, reflecting ongoing market challenges. Over the past week and month, the company has seen significant decreases, contrasting with positive performance in the S&P/TSX 60 index. Long-term metrics reveal substantial declines and financial difficulties, including a high Debt to EBITDA ratio.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Strategic Entities
Held in 0 Schemes (0%)
Held by 0 Foreign Institutions (0%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 8.29% vs -16.59% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 40.62% vs -52.38% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -8.81% vs 6.37% in Dec 2023
YoY Growth in year ended Dec 2024 is 27.69% vs -21.17% in Dec 2023






